Completed PHASE1 INTERVENTIONAL 1-arm NCT00733720

Buprenorphine Naltrexone-P1 A-Cocaine

Attenuation of Opioid Effects of Three Different Doses of Sublingual Buprenorphine / Naloxone by Oral Naltrexone in Healthy Volunteers

Sponsor: National Institute on Drug Abuse (NIDA)

Conditions Cocaine-related Disorders

Interventions Suboxone

Updated 7 times since 2017 Last updated: Jan 11, 2017 Started: Aug 31, 2008 Primary completion: Dec 31, 2008 Completion: Jan 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Cocaine-related Disorders, this trial is completed. The trial is conducted by National Institute on Drug Abuse (NIDA) and has accumulated 7 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute on Drug Abuse (NIDA)

Data source: National Institute on Drug Abuse (NIDA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Francisco, United States